Gilead SciencesGILDRevenue: is the business selling more than it used to?
$29.4B+2% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $29.4B in 2025, compounding +3% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $30.5B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDNet income: how much of that revenue becomes profit?
$8.5B+1673% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $8.5B in 2025, compounding +23% a year over three years. Earnings per share moved -151% over the last twelve months. Trailing twelve-month profit stands at $-3.2B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDHow fast is it growing, year by year?
+2.4%revenue growth, FY 2025
Off the axis: 2014 earnings +293.5% · 2021 earnings +4961.0% · 2025 earnings +1672.9% - rebounds off a collapsed prior year.
→Revenue grew +2% in 2025 against a five-year average of +4%. 2014's +294% earnings rebound off a collapsed base and 2021's +4961% earnings rebound off a collapsed base and 2025's +1673% earnings rebound off a collapsed base sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDRevenue per share: is your slice growing as fast as the company?
$23.46revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $23.46 in 2025, compounding +3% a year - in line with GILD's own +3%, so the share count is not distorting your slice. Free cash flow per share stands at $7.53.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDFree cash flow: what is left in real cash after everything?
$9.5B−8% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $9.5B in 2025, compounding +4% a year since 2022. The trailing twelve months stand at $12.9B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→32 cents of every sales dollar became free cash in 2025, and it has held steady since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 41% of revenue (stock compensation 3%, capital spending 2%). That share has risen since 2016, so the cost of competing is climbing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in 3 of the last 5 years, most recently +503% against +2%. Each additional dollar of sales is landing more profitably than the last - the definition of operating leverage.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin widened 7 points to 34% since 2022. After everything, 29 cents of each sales dollar reaches net profit. GILD doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -27% and ROCE of 21% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDWhat has the market paid for GILD over time?
6.1xP/S today
→At 6.1x sales, the market is paying +115% more than GILD's own 11-year median of 2.9x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDWhat cash return does the business throw off per dollar of market value?
6.9%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 6.9% of annual free cash flow, less than its 11-year median of 11.3% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDCould it handle its debt if things went wrong?
→Debt of $26.2B sits against $3.2B of cash, or 2.2x shareholders' equity. Earnings don't currently cover the interest bill at all.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDIs the company's own capital growing?
→The company's own capital shrank from $22.8B in 2023 to $11.8B (-48%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDHow much goes back, and how much leaks out as stock comp?
→Shareholders received $1.9B in buybacks and $4.0B in dividends in 2025. Stock compensation issued $894M of new shares in the same year, offsetting 15% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDHow fast is your ownership being diluted - or concentrated?
→The share count shrank 0.0% in 2025, averaging 0.2% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDIs the dividend cheque growing?
→The dividend per share reached $3.19 in 2025, compounding +3% a year since 2020.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDCan it afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The dividend consumed 47% of profit and 42% of free cash flow in 2025. That leaves room to keep paying through a weak year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDDoes GILD earn more on its capital than that capital costs?
→GILD earns 21.2% on the capital it employs, well above the 10% most investors treat as the cost of capital. It was 14.1% in 2022, so the trend is up, though the path has been bumpy.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDGILD has issued or retired shares - did shareholders end up better off?
→GILD has shrunk its share count -21% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is +342% over the same years.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Gilead SciencesGILDAre the people running it buying or selling?
→Insiders sold $26M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 26 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30